In particular, prolgolimab demonstrated more stable interaction with PD-1, induced higher T-cell activation in cell-based bioassays, did not induce ADCP and showed more robust tumor growth inhibition in laboratory animals as compared to the aforementioned drugs. Here, PDCD1 is linked to neoplasm.